GlassScriptPhysician profile
Peiman Berdjis
NPI 1326150590
$22,749.41
in general payments reported to CMS, 2019-2025
55 companies · $5,536 in 2025
The $5,536 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,709 · 2020: $1,612 · 2021: $3,107 · 2022: $2,234 · 2023: $2,955 · 2024: $4,596 · 2025: $5,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,687.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,500.22 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $2,338.23 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,525.40 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,400.04 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Amarin Pharma, INC. | $1,009.88 | 2019-2023 | |
| Axsome Therapeutics, INC. | $952.39 | 2023-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $890.59 | 2021-2025 | |
| Lilly USA, LLC | $759.32 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $756.36 | 2020-2025 | Synjardy, Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $662.63 | 2021-2025 | |
| Gilead Sciences, INC. | $654.15 | 2019-2025 | Yeztugo |
| Pfizer INC. | $599.53 | 2019-2024 | |
| Lundbeck LLC | $589.90 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $485.36 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Takeda Pharmaceuticals U.S.A., INC. | $482.75 | 2019-2025 | Trintellix |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peiman Berdjis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.